Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a induction dosing in chronic hepatitis C genotype 1
ACTRN12605000488606Phase 4Completed
- Sponsor
- Roche
- Start
- Feb 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of interferon alfa and ribavirin in chronic hepatitis C virus infection (2 arms), sponsored by Roche. Primary endpoint: Sustained virological response. Started Feb 2009; status: completed.
02
Drugs
interferon alfaribavirin
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12605000488606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000488606.